- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 14161
Historique des publications depuis 10 ans
|
831
|
916
|
1149
|
1277
|
1362
|
1526
|
1478
|
1392
|
1194
|
359
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 19681 |
301 |
| The Trustees of the University of Pennsylvania | 4282 |
301 |
| The Board of Trustees of the Leland Stanford Junior University | 6296 |
192 |
| Memorial Sloan-Kettering Cancer Center | 1887 |
176 |
| Regeneron Pharmaceuticals, Inc. | 4140 |
173 |
| Board of Regents, The University of Texas System | 5689 |
154 |
| Immatics Biotechnologies GmbH | 1146 |
154 |
| Novartis AG | 11042 |
137 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2822 |
128 |
| The General Hospital Corporation | 4675 |
90 |
| Autolus Limited | 249 |
80 |
| City of Hope | 966 |
80 |
| Dana-Farber Cancer Institute, Inc. | 2529 |
74 |
| CRISPR Therapeutics AG | 353 |
73 |
| Alpine Immune Sciences, Inc. | 79 |
71 |
| Baylor College of Medicine | 926 |
68 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3356 |
67 |
| Lentigen Technology, Inc. | 98 |
66 |
| Juno Therapeutics, Inc. | 365 |
64 |
| The Johns Hopkins University | 5575 |
63 |
| Autres propriétaires | 11649 |